中心型非小细胞肺癌立体定向体部放疗的长期临床结局与安全性特征
该研究回顾性分析了2008至2014年间103例中心型非小细胞肺癌患者的110个肿瘤,接受立体定向体部放疗,最常见方案为50 Gy分5次(59%)和48 Gy分4次(30%)。5年局部控制率89%、区域控制率77%、无远处转移生存率82%,中位总生存3.5年、5年总生存率35%;3级放射性肺炎发生率0.97%,晚期≥3级毒性发生率9.7%。
要点
- 中心型非小细胞肺癌立体定向体部放疗的5年局部控制率为89%。
- 3级放射性肺炎发生率为0.97%,晚期≥3级毒性发生率为9.7%。
- 尽管局部控制率优异,患者仍存在区域和远处失败风险。
核心结论
- 中心型非小细胞肺癌的立体定向体部放疗可提供高局部控制率;尽管局部控制优异,患者仍面临区域和远处失败风险;3级肺炎发生率与既往报道一致;观察到可能归因于立体定向体部放疗的低4-5级毒性发生率。
研究设计与样本
- 回顾性分析前瞻性收集的立体定向体部放疗数据库,纳入2008年至2014年间接受立体定向体部放疗的中心型非小细胞肺癌患者103例,共110个中心型肺部肿瘤。
主要发现
- 中位年龄74岁(范围40-95岁),存活患者中位随访时间50个月,平均肿瘤大小20 mm(范围5-70 mm)。
- 5年局部控制率、区域控制率和远处控制率分别为89%、77%和82%;中位总生存期3.5年,5年总生存率35%。
- 未发现治疗变量与肿瘤控制或其他临床结局相关。
- 单例患者发生3级放射性肺炎(0.97%);晚期≥3级毒性发生率为9.7%(3级7.7%、4级0.97%、5级0.97%),包括肺炎(3.9%)、支气管坏死(2.9%)、心肌功能障碍(1.9%)和心力衰竭加重(0.97%)。
关键数值与推荐
- 最常见剂量分割方案为50 Gy分5次(59%)和48 Gy分4次(30%)。
- 毒性分级采用美国国家癌症研究所常见毒性事件标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Previous studies suggest that stereotactic body radiation therapy (SBRT) is associated with higher toxicity rates for central lung tumors relative to peripheral tumors when using 3 fraction SBRT. The initial results from Radiation Therapy Oncology Group study 0813 suggest a safe toxicity profile of SBRT administered in 5 fractions for central non-small cell lung cancer (NSCLC). We reviewed our institutional data to evaluate the safety and efficacy of SBRT for central NSCLC. METHODS AND MATERIALS: We reviewed our prospectively collected SBRT database for patients with central NSCLC who received SBRT between 2008 and 2014. The most frequent dose and fractionations were 50 Gy in 5 fractions (59%) and 48 Gy in 4 fraction (30%). Local control (LC), regional control, metastasis-free survival, and overall survival were calculated using Kaplan-Meier estimates. The National Cancer Institute Common Terminal Criteria for Adverse Events were used for toxicity grading. RESULTS: A total of 110 central lung tumors in 103 patients were included. The median age was 74 years (range, 40-95 years), and the median follow-up time of living patients was 50 months. The mean tumor size was 20 mm (range, 5-70 mm). The 5 year rate of LC, regional control, and distant control was 89%, 77%, and 82%, respectively. The median and 5-year overall survival were 3.5 years and 35%, respectively. No treatment variables were associated with tumor control or other clinical outcomes. A single patient experienced grade 3 radiation pneumonitis (0.97%). The rate of late toxicity grade ≥3 was 9.7% (grade 3, 7.7%; grade 4, 0.97%; grade 5, 0.97%) and included pneumonitis (3.9%), bronchial necrosis (2.9%), myocardial dysfunction (1.9%), and worsening heart failure (0.97%). CONCLUSIONS: SBRT for central NSCLC provides high rates of LC. Despite excellent LC, patients remain at risk for regional and distant failure. The rate of grade 3 pneumonitis was consistent with that of prior reports. We observed low rates of grade 4-5 toxicity potentially attributable to SBRT. Our results contribute to the growing body of data in support of the safety of SBRT for central NSCLC.
引用
- Arnett ALH, Mou B, Owen D, et al. Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC. Adv Radiat Oncol. 2019. PMID: 31011688. doi:10.1016/j.adro.2019.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。